Enter Title

Name that PD1/PDL1 Inhibitor

100

Dosing includes 840 q2 weeks, 1200 q3 weeks or 1680 q 4 weeks in its mono indications 

Tecentriq

200

This agent now has an indication in unresectable, malignant pleural mesothelioma, as first line treatment, in combination with ipilimumab

Opdivo

300

This is the only agent indicated for the treatment of adult patients with unresectable, Stage III non-small cell lung cancer whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.

Imfinzi

400

This agent utilizes weight based dosing.

Imfinzi

500

The only agent with superior OS results in first line monotherapy down to PDL1 1% or greater.  

Keytruda 

Efficacy-What’s the (End)point?

100

Keytruda‘s OS and HR in KN 189

NR vs 11.3 months, and HR of .49

200

What is the OS median in months and HR in CM 227?

17.1 months vs 14.9 months, HR of .79

300

What is the OS median in months and HR of CM 9LA?

15.6 months vs 10.9 months, HR of .66

400

What was Tecentriq’s OS in median in months and HR in Impower 110?

20.2 months vs 13.1 months, HR of .59

500

Keytruda‘s OS in median in months and HR in Keynote 24

30 months vs 14.2 months, HR of .60

Safety-It’s All in the Numbers

100

The discontinuation rate due to AEs in Keynote 42

19%

200

The discontinurion rate due to AEs in Impower 110 

6%

300

Percentage of serious AEs in CM 227

58%

400

Percentage of patients that had at least 1 treatment withheld due to treatment in CM 9LA 

56%

500

Percentage of patients that received Ipi Nivo for greater than 6 months, and greater for 1 year, in CM 227

39% and 23%

Indications

100

Keytruda is the only PD1 with an indication in this setting. 

Monotherapy down to PDL1 1% or greater 

200

Tecentriq‘s quad regimen consists of this.

Tecentriq, in combination with bevacizumab, paclitaxel, and carboplatin

300

This agent is indicated in combination with carbo and etoposide In the first line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC)

Tecentriq

400

The dosing regimen for Ipi Nivo plus chemo (CM 9LA) indication. 

360 mg every 3 weeks with ipi 1 mg/kg every 6 weeks and 2 cycles of platinum-doublet chemo.

500

Tecentriq’s indication based off Impower 110

the first-line treatment of adult patients with metastatic NSCLC whosetumors have high PD-L1 expression (PD-L1 stained ≥ 50% of tumor cells [TC ≥ 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering ≥ 10% of the tumor area [IC ≥ 10%] ), as determined by an FDA- approved test, with no EGFR or ALK genomic tumor aberrations.